BioReliance launches novel genotoxicity screen

Oct. 24, 2007 - PRLog -- BioReliance (Rockville, Maryland) has contracted with Gentronix (Manchester, UK) to offer its GreenScreen HC in vitro assay as a major part of BioReliance’s portfolio of genotoxicity screening services.

Use of GreenScreen HC in conjunction with Ames II assays allows testing for genotoxic potential earlier in the preclinical development process, using only a few milligrammes of test compound instead of the gramme quantities required by current ICH regulatory tests.  The method also minimises false positives, notes David Bruning, BioReliance’s senior director, toxicology operations.  The assay can detect multiple mechanistic classes of genotoxic agents, including aneugens, and is easily adapted to automatic robotic platforms.

GreenScreen HC is a unique human cell-based genotoxicity screening assay that links the regulation of the human growth arrest and DNA damage (GADD45a) gene to the production of green fluorescent protein (GFP).  Cells that have suffered DNA damage following exposure to a test compound express higher levels of detectable GFP. Article submitted by www.jobs4dd.com.

# # #

www.jobs4dd.com is a specialist online recruitment service for the clinical trial and drug development sectors. Latest news and jobs in the industry are listed on a daily basis. Latest international clinical research jobs, CRM jobs, regulatory affairs jobs, data management jobs, statistician jobs, pharmacovigilance jobs and many more vacancies are listed on the www.jobs4dd.com website. Visit our news archive section at www.jobs4dd.com/news-archive.php

Website: www.jobs4dd.com